한글목차

세계의 성인 백신 시장은 2025년에는 196억 6,000만 달러로 추정되며, 2032년에는 350억 5,000만 달러에 달할 것으로 예측되며, 2025-2032년에 CAGR 8.6%로 성장할 전망입니다.

도표. 성인 백신 시장 점유율(%), 2025년 지역별

세계 성인용 백신 시장 성장의 원동력은 정부 및 민간 기업의 성인 예방접종 프로그램에 대한 투자 증가입니다. 성인 백신 접종은 심각한 질병과 감염으로부터 사회적 약자를 보호할 수 있는 수단으로 인기를 얻고 있습니다. 백신에 대한 인식이 높아짐에 따라 더 많은 사람들이 백신 접종에 대한 인식이 높아지면서 더 많은 사람들이 백신을 접종하고 있습니다. 또한 기존 성인용 백신의 적응증 확대와 새로운 제형 개발로 전 세계 성인 인구에 영향을 미치는 다양한 질병에 대한 예방이 강화되고 있습니다. 그러나 높은 개발 비용과 신흥 국가의 부족한 백신 접종 인프라가 시장 개발의 걸림돌로 작용하고 있습니다.

시장 역학:

세계 성인 백신 시장의 성장은 성인들 사이에서 독감, 수막염, 폐렴구균 감염 등의 질병 유병률이 증가하고 있는 것에 기인합니다. 세계보건기구(WHO)에 따르면 계절성 독감은 매년 전 세계에서 약 300만-500만 명의 중증 환자와 29만-65만 명의 호흡기 질환 사망자를 발생시킵니다. 헬스케어 지출 증가, 백신 접종 프로그램을 통한 정부의 적극적인 지원, 새로운 백신의 도입이 시장 성장의 원동력이 되고 있습니다. 그러나 신흥 국가에서의 낮은 인지도, 신규 백신 개발에 따른 높은 R&D 비용, 보관의 필요성 등이 시장 성장에 걸림돌이 될 수 있습니다. 냉장보관이 필요 없는 내열성 백신과 성인용 혼합백신의 개발은 시장 개발의 기회를 제공할 수 있습니다.

본 조사의 주요 특징

• 세계의 성인용 백신 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 동안 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
• 또한 다양한 부문에 걸친 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
• 이 보고서에서는 세계 성인용 백신 시장의 주요 기업 개요을 기업 개요, 제품 포트폴리오, 주요 특징, 주요 성과, 전략 등의 파라미터를 기준으로 정리하여 전해드립니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계의 성인 백신 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 성인 백신 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 리포트 설명
  • 시장의 정의와 범위
• 개요
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
• 영향 분석
• 시장 동향
• 주요 발전
• 규제 시나리오
• 인수와 제휴 시나리오
• 자금조달과 투자
• PEST 분석
• Porter의 산업 분석

제4장 세계의 성인 백신 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• 전체적인 영향
• 정부 구상
• 시장에 대한 COVID-19의 영향

제5장 세계의 성인 백신 시장, 백신별, 2020-2032년(10억 달러)

• 인플루엔자
• 파상풍, 디프테리아, 백일해(Td/Tdap)
• 수두
• 인유두종바이러스
• 대상포진
• 홍역, 풍진, 볼거리(MMR)
• 폐렴구균
• 간염
• 기타

제6장 세계의 성인 백신 시장, 백신 유형별, 2020-2032년, (10억 달러)

• 1가
• 다가

제7장 세계의 성인 백신 시장, 기술별, 2020-2032년, (10억 달러)

• 생약독화 백신
• 불활성화 바이러스/세균 백신
• 톡소이드 백신
• 재조합 백신
• 결합 백신

제8장 세계의 성인 백신 시장, 지역별, 2020-2032년, (10억 달러)

• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제9장 경쟁 구도

• 기업 개요
  • GlaxoSmithKline plc
  • Merck &Co., Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • AstraZeneca
  • Johnson &Johnson
  • Novavax, Inc.
  • Moderna, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Bavarian Nordic
  • Dynavax Technologies Corporation
  • BioNTech S
  • Emergent BioSolutions Inc.
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech
  • Sinovac Biotech Ltd.

제10장 애널리스트의 권장사항

제11장 참고 문헌과 조사 방법

• 참고 문헌
• 조사 방법

영문목차

Global Adult Vaccines Market is estimated to be valued at USD 19.66 Bn in 2025 and is expected to reach USD 35.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.

Figure. Adult Vaccines Market Share (%), By Region 2025

Global adult vaccines market growth is driven by increasing investments by governments and private firms in adult vaccination programs. Adult vaccinations have gained popularity as these protect vulnerable groups from serious diseases and infections. Growing awareness about available vaccines and their benefits for adults has prompted more individuals to get vaccinated. Moreover, expansion of indications for existing adult vaccines and development of new formulations have strengthened prevention against various diseases affecting the adult population worldwide. However, high development costs and lack of adequate vaccination infrastructure in developing nations can hamper the market growth.

Market Dynamics:

Global adult vaccines market growth is driven by rising prevalence of diseases such as influenza, meningococcal meningitis, pneumococcal infection, and others among adults. According to the World Health Organization, seasonal influenza results in severe illness in around 3-5 million cases and 290,000-650,000 respiratory deaths globally every year. Increasing healthcare expenditures, favorable government support through vaccination programs and introduction of novel vaccines can drive the market growth. However, low awareness in developing countries, high R&D costs associated with development of new vaccines and storage requirements can hamper the market growth. Development of thermostable vaccines without refrigeration needs and combined adult vaccine formulations can offer opportunities for market players.

Key Features of the Study:

• This report provides in-depth analysis of the global adult vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global adult vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline, Sanofi Pasteur, Merck, Novavax, Pfizer, and CSL Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global adult vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adult vaccines market

Detailed Segmentation-

• By Vaccines
  • Influenza
  • Tetanus, Diphtheria, Pertussis (Td/Tdap)
  • Varicella
  • Human Papillomavirus
  • Zoster
  • Measles, Mumps, Rubella (MMR)
  • Pneumococcal
  • Hepatitis
  • Others
• By Vaccine Type
  • Monovalent
  • Multivalent
• By Technology
  • Live Attenuated Vaccines
  • Inactivated Viral/Bacterial Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • AstraZeneca
  • Johnson & Johnson
  • Novavax, Inc.
  • Moderna, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Bavarian Nordic
  • Dynavax Technologies Corporation
  • BioNTech S
  • Emergent BioSolutions Inc.
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech
  • Sinovac Biotech Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Vaccines
  • Market Snapshot, By Vaccine Type
  • Market Snapshot, By Technology
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Adult Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Adult Vaccines Market, By Vaccines, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Influenza
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Tetanus, Diphtheria, Pertussis (Td/Tdap)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Varicella
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Human Papillomavirus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Zoster
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Measles, Mumps, Rubella (MMR)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pneumococcal
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hepatitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Adult Vaccines Market, By Vaccine Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Monovalent
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Multivalent
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Adult Vaccines Market, By Technology, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Live Attenuated Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inactivated Viral/Bacterial Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Toxoid Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Recombinant Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Conjugate Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Adult Vaccines Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccines, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccines, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccines, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccines, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccines, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccines, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • GlaxoSmithKline plc
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi Pasteur
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novavax, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Moderna, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Bavarian Nordic
  • Dynavax Technologies Corporation
  • BioNTech S
  • Emergent BioSolutions Inc.
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech
  • Sinovac Biotech Ltd.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact